Mo1090 DIRECT-ACTING ORAL ANTICOAGULANT (DOAC) USE IS NOT ASSOCIATED WITH INCREASED RISK OF COMPLICATIONS AFTER POLYPECTOMY

Direct-acting oral anticoagulants (DOACs) such as rivaroxaban, apixaban, dabigatran, and edoxaban represent 62% of new anticoagulation prescriptions. Compared to warfarin, DOACs increase the risk of gastrointestinal bleeding but reduce the risk of stroke. Little is known about the risk of complications after polypectomy in patients with active DOAC use. We aimed to determine the risk of complications after polypectomy in this population.

Source: Gastrointestinal Endoscopy - May 30, 2018 Category: Gastroenterology Authors: Jessica X. Yu, Melissa Oliver, Jody Lin, Matthew S. Chang, Allison J. Kwong, Berkeley Limketkai, Roy M. Soetikno, Jayanta Bhattacharya, Tonya R. Kaltenbach Tags: Monday abstract Source Type: research